Clinical Research Directory
Browse clinical research sites, groups, and studies.
Does Addition of Medial Pterygoid Muscle Injection Improve the Outcome of Botulinum Toxin Therapy for Masticatory Myofascial Pain Syndrome?
Sponsor: Fayoum University
Summary
Masticatory myofascial pain syndrome (MMPS) is a common and debilitating orofacial pain condition characterized by localized or referred pain originating from trigger points in the masticatory muscles. The condition significantly impairs quality of life, affecting mastication, speech, and psychosocial well-being. The masseter and temporalis muscles are the most frequently targeted muscles in conventional botulinum toxin type A (BoNT-A) therapy for MMPS; however, the medial pterygoid muscle, a primary jaw-closing muscle, is often overlooked due to its deep anatomical location and the technical challenges associated with its injection.
Official title: Does Addition of Medial Pterygoid Muscle Injection Improve the Outcome of Botulinum Toxin Therapy for Masticatory Myofascial Pain Syndrome? A Randomized Controlled Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
111
Start Date
2026-09-01
Completion Date
2027-05-01
Last Updated
2026-08-19
Healthy Volunteers
No
Conditions
Interventions
conventional BoNT-A treatment
botulinum toxin type A injection into the bilateral masseter and temporalis muscles
Placebo
placebo/sham injection protocol
conventional treatment plus medial pterygoid injection
masseter and temporalis injections as Group A, in addition to targeted injection of the clinically involved medial pterygoid muscle
Locations (1)
MUST University
Cairo, Cairo Governorate, Egypt